spacer
home > white papers > eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials - Clinical Ink
WHITE PAPERS

Clinical Ink

phone 1-800-301-5033
email info@clinicalink.com
web http://www.clinicalink.com
email 525 Vine Street, Suite 130, Winston-Salem, NC 27101

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

More sponsors and CROs are looking for new ways to better leverage investigative site relationships to improve clinical trial performance. To this end, some clinical organizations have adopted electronic source (eSource) to help improve study quality and efficiency - for both sponsor and site. Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. As SureSource adoption increased, study teams began to see an improvement in data quality, operational efficiency and ease of use compared to traditional methods (paper and EDC). A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Safe’n’Spray™, the smart electronic concept device with child-resistant and locking features, wins the ‘Best Innovation In Drug Delivery Device’ Award at Pharmapack 2020

On February 5th, during the Pharmapack Awards Ceremony, Safe’n’Spray, Nemera’s smart electronic concept device with child-resistant and locking features, was celebrated as the “Best Innovation in Drug Delivery Device”.
More info >>


White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>


Industry Events

BioTrinity 2020

28-29 April 2020, Etc Venues, London

BioTrinity is a long-running and highly regarded two day life sciences conference that takes place in Central London from 28-29 April. BioTrinity focuses on partnering, investment and collaboration and aims to inspire growth and create opportunities for all who attend. The core delegate mix includes early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement